⚠ Evidence warning: Clinical trials or other evidence do not support the claim that hawthorn prevents heart attacks, relieves stable, microvascular or vasospastic angina, eases atrial fibrillation and aids recovery after a heart attack. This page keeps it as a report of what people, websites or other media say.

Hawthorn for Cardioprotection and Angina

Cardioprotection and Angina — scientific infographic poster

Beyond its formally approved indication for New York Heart Association (NYHA) Class II heart failure, Hawthorn has been used for over four centuries in European herbal medicine as a general "heart tonic" a gentle daily preparation for cardiac strengthening, prevention of ischemic events, and management of stable angina. Modern phytochemistry has explained much of this traditional use: Hawthorn flavonoids prolong the cardiac effective refractory period (anti-arrhythmic), oligomeric proanthocyanidins (OPCs) are among the most potent reactive-oxygen-species scavengers in the plant kingdom (cardioprotective against ischemia-reperfusion injury), and the combined OPC + flavonoid fraction increases coronary blood flow through endothelial nitric oxide release (anti-anginal). This deep-dive examines the cardioprotective and anti-anginal evidence, traces the long European history of the "heart herb" from Dioscorides through Grieve's 1931 Modern Herbal, and outlines how Hawthorn has been positioned for people with ischemic heart disease, stable angina, or atrial fibrillation.


Table of Contents

  1. The European "Heart Tonic" Tradition (400+ Years)
  2. From Dioscorides to Maud Grieve's Modern Herbal
  3. OPC Antioxidant Cardioprotection
  4. Ischemia/Reperfusion Injury — Animal Evidence
  5. The Anti-Arrhythmic Mechanism
  6. Stable Angina — Clinical Evidence
  7. Atrial Fibrillation Considerations
  8. Coronary Blood Flow Enhancement
  9. Post-Myocardial-Infarction Recovery
  10. Where Hawthorn Has Been Proposed in Heart Care
  11. Key Research Papers
  12. Connections
  13. Featured Videos

The European "Heart Tonic" Tradition (400+ Years)

Hawthorn (Crataegus) has been the European traditional remedy for cardiac complaints since at least the sixteenth century, when it first appears in vernacular herbals as a treatment for "weakness of the heart," "palpitations," and "cardiac exhaustion." By the eighteenth century it was an established item in continental European pharmacopoeias under the indication of tonicum cordis — a tonic for the heart.

The phrase "heart tonic" in the herbalist's lexicon meant something specific that has no direct equivalent in modern allopathic pharmacology. A tonic was understood as a long-term restorative agent that strengthened an organ's function without producing dramatic acute effects — closer in spirit to a vitamin or a structural support than to a drug. The patient was expected to take a tonic daily for months or years, not for a discrete pharmacologic event, and the benefit was expected to emerge slowly. This is in fact the pattern modern trials have confirmed for Hawthorn: the effect develops over 6-8 weeks, the magnitude is modest, and continuous long-term use is the well-established mode.

The most influential nineteenth-century clinical advocate was Irish-American physician Charles Cullen Greene, whose 1896 paper in the New York Medical Journal described striking clinical improvement in patients with "cardiac decompensation" treated with Hawthorn tincture. Greene's observations spread rapidly through North American eclectic and homeopathic practice and back to Europe, where they reinforced the existing herbal tradition and inspired more systematic phytochemical investigation in the twentieth century.

By the 1930s, German physiologists had begun to isolate the active fractions. By the 1970s, the OPC content of the leaf-and-flower extract had been characterized and standardized. The 1984 German Commission E approval was followed by two large modern heart-failure trials, SPICE and HERB CHF. Both were null on their main outcomes, and HERB CHF found more adverse events in the hawthorn group.

In SPICE (2,681 patients with heart failure, 900 mg a day of the WS 1442 extract or placebo for 24 months), the extract had no significant effect on the main outcome, time to the first cardiac event (hazard ratio 0.95), and the trend toward fewer cardiac deaths was not statistically significant; adverse events were comparable in both groups. The HERB CHF trial gave 120 people with heart failure (New York Heart Association class II–III), all on standard medicines, 450 mg of hawthorn twice a day or placebo for 6 months. It found no difference in 6-minute walking distance, quality of life, exercise capacity, hormone markers, or markers of oxidative stress and inflammation; a modest difference in left ventricular ejection fraction favoured hawthorn, and there were significantly more adverse events in the hawthorn group, most of them not heart-related. Its authors concluded that hawthorn "provides no symptomatic or functional benefit when given with standard medical therapy to patients with heart failure."

Back to Table of Contents

From Dioscorides to Maud Grieve's Modern Herbal

The earliest documented medicinal use of Hawthorn appears in the first-century AD De Materia Medica of the Greek physician Pedanius Dioscorides, who recommended the fruit and bark for digestive complaints rather than for cardiac use. The specifically cardiac indication emerges later, in the early-modern European herbal tradition.

Key historical sources documenting the cardiac use:

Grieve's entry captures the early-twentieth-century state of knowledge well. By her account, Hawthorn was used clinically for:

This pattern of use — spanning structural heart disease, arrhythmia, edema, and the cardio-emotional crossover — is remarkably close to the indications modern phytochemistry has validated. The traditional knowledge was substantially correct; what modern research has added is mechanism, standardization, and dose-response.

Back to Table of Contents

OPC Antioxidant Cardioprotection

Oligomeric proanthocyanidins (OPCs) are among the most potent free-radical scavengers in the plant kingdom on a mole-for-mole basis. They sit alongside the proanthocyanidins of grape seed extract, pine bark, and dark cocoa as the dominant dietary source of high-potency polyphenolic antioxidants. The mechanism is direct hydrogen-atom transfer from the catechin / epicatechin hydroxyl groups to reactive oxygen species (ROS), neutralizing them before they can damage cellular structures.

In the cardiovascular system, the relevant reactive oxygen species are:

Hawthorn OPCs scavenge all of these species in cell-free assays at concentrations achievable with oral dosing. The clinical translation has been studied most rigorously in:

  1. Animal models of ischemia/reperfusion injury (see next section)
  2. Markers of oxidative stress in heart failure patients (the HERB CHF trial, 450 mg twice daily for 6 months, found no difference from placebo)
  3. Markers of endothelial function (modestly improved flow-mediated dilation in some trials)

The size of the antioxidant effect in humans is modest compared to the in vitro potency, because of the substantial first-pass metabolism, bioavailability limitations, and competition from the body's endogenous antioxidant systems.

Back to Table of Contents

Ischemia/Reperfusion Injury — Animal Evidence

Ischemia/reperfusion (I/R) injury is the paradoxical cellular damage that occurs not during the ischemic interval itself but immediately upon restoration of blood flow. It is the mechanism that limits the clinical benefit of reperfusion after myocardial infarction (after percutaneous coronary intervention (PCI) or thrombolysis), liver transplantation, organ transplant generally, and stroke recanalization. The injury is driven by a burst of reactive oxygen species generation during the first minutes of reperfusion, when mitochondria suddenly resume electron transport in the presence of accumulated metabolic substrates and oxygen.

Hawthorn extract has been tested in multiple animal I/R models with consistently favorable results:

The animal evidence has not been directly translated to large human trials of Hawthorn for acute myocardial infarction or for cardioprotection during planned cardiac surgery, primarily because the regulatory and funding pathway for such trials of a non-patentable botanical is challenging. Practitioners cite this animal work as the rationale for long-term Hawthorn use as an add-on in people with established ischemic heart disease.

Back to Table of Contents

The Anti-Arrhythmic Mechanism

Hawthorn extracts prolong the cardiac effective refractory period (ERP) in isolated cardiac muscle preparations — an electrophysiologic effect that is broadly anti-arrhythmic for re-entrant arrhythmias such as paroxysmal supraventricular tachycardia, atrial flutter, and many cases of ventricular tachycardia. The mechanism appears to involve mild blockade of repolarizing potassium currents, similar in concept (though much weaker in magnitude) to the Class III antiarrhythmic drug amiodarone. In isolated guinea pig hearts, a hawthorn extract lengthened the effective refractory period by up to 10%, while epinephrine, digoxin, milrinone and amrinone shortened it (Joseph 1995). In anaesthetized rats with a blocked coronary artery, a hawthorn (Crataegus meyeri) flower extract cut ventricular ectopic beats from 1,494 to 634 and shortened the time spent in ventricular fibrillation (Garjani 2000).

The clinical correlate cited is a SPICE trial subgroup finding: in patients with left ventricular ejection fraction (LVEF) of 25–35%, WS 1442 reduced sudden cardiac death by 39.7% (hazard ratio 0.59; see the Heart Failure deep-dive). The trial's main outcome, time to the first cardiac event, did not differ from placebo (hazard ratio 0.95), and the trend toward fewer cardiac deaths was not statistically significant. Sudden cardiac death in heart failure patients is overwhelmingly due to ventricular arrhythmia, and the subgroup reduction is consistent with the anti-arrhythmic effect documented in isolated heart-muscle preparations.

Beyond the SPICE signal, smaller observational studies and case reports suggest reduced frequency of palpitations and benign ectopy in patients taking Hawthorn for general cardiovascular wellness. For atrial fibrillation specifically, see the next section.

An important contrast: while Hawthorn is broadly anti-arrhythmic and pro-arrhythmic effects are not seen in trials, it has not been tested as a replacement for established antiarrhythmic drugs in people with documented dangerous arrhythmias. Sustained ventricular tachycardia, cardiomyopathy severe enough for an automatic implantable cardioverter-defibrillator (AICD), and persistent atrial fibrillation are treated with established rate-control and rhythm-control strategies; where Hawthorn is used, it is used alongside them, not as primary therapy.

Back to Table of Contents

Stable Angina — Clinical Evidence

The European clinical literature on Hawthorn for stable angina is older and less rigorous than the heart failure data, because most modern trials have focused on the heart failure indication that received Commission E approval. However, multiple older European observational and uncontrolled studies, and the proposed mechanism (anti-arrhythmic + coronary vasodilator + antioxidant), are cited for adjunctive use:

Practitioners who use Hawthorn for stable angina describe it as:

Back to Table of Contents

Atrial Fibrillation Considerations

Atrial fibrillation is the most common sustained arrhythmia, affecting an estimated 6 million Americans, with prevalence climbing steeply with age. Modern management involves anticoagulation for stroke prevention (warfarin or a direct oral anticoagulant), rate control (typically a beta-blocker or calcium channel blocker), and selective rhythm control (cardioversion, antiarrhythmics, ablation) in symptomatic patients.

Hawthorn's role in atrial fibrillation has not been well studied in dedicated trials, but the mechanistic profile suggests several potential roles:

Important cautions:

Back to Table of Contents

Coronary Blood Flow Enhancement

One of the older traditional uses of Hawthorn was as a "coronary vasodilator" for patients with ischemic heart disease. Modern phytochemistry has confirmed this effect through the endothelial nitric oxide synthase pathway already described.

The clinical relevance:

The relevance to specific clinical contexts:

Back to Table of Contents

Post-Myocardial-Infarction Recovery

Practitioners cite the animal I/R data as a basis for chronic Hawthorn use in people recovering from myocardial infarction or undergoing cardiac rehabilitation, as one element of a comprehensive cardioprotective strategy. The conventional foundation remains:

The theoretical benefits proposed for Hawthorn as an add-on to this regimen are antioxidant cardioprotection against ongoing oxidative stress, mild anti-arrhythmic effect reducing the small but real residual sudden cardiac death risk in post-MI patients with reduced ejection fraction, and mild improvement in exercise tolerance during the recovery and rehabilitation phase.

None of this is established by dedicated randomized trials in post-MI populations — the existing trial data is for chronic stable heart failure, not for post-MI cardioprotection — and the mechanistic rationale comes from animal studies. On safety, SPICE found adverse events comparable to placebo, while HERB CHF reported significantly more adverse events in the hawthorn group, most of them not heart-related. Hawthorn has not been tested as a replacement for any of the guideline-directed treatments listed above.

Back to Table of Contents

Where Hawthorn Has Been Proposed in Heart Care

Beyond the formally approved NYHA Class II heart failure indication and the blood pressure data, the add-on uses proposed for Hawthorn in heart care are:

Hawthorn has not been shown to work as:

A 2020 systematic review written for the Australian heart-failure guidelines placed hawthorn extract among the supplements whose studies "were too small or underpowered to properly appraise clinical outcomes"; of all the supplements reviewed, only omega-3 polyunsaturated fatty acids received a positive recommendation in those guidelines.

Back to Table of Contents

Key Research Papers

  1. Veveris M, Koch E, Chatterjee SS (2004). Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci 74(15):1945-1955. — PubMed PMID: 14761675
  2. Al Makdessi S et al. (1996). Myocardial protection by pretreatment with Crataegus oxyacantha: an assessment by means of the release of lactate dehydrogenase by the ischemic and reperfused Langendorff heart. Arzneimittelforschung 46(1):25-27. — PubMed PMID: 8821513
  3. Jayalakshmi R, Devaraj SN (2004). Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats. J Pharm Pharmacol 56(7):921-926. — PubMed
  4. Wang J, Xiong X, Feng B (2013). Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evid Based Complement Alternat Med. — PubMed
  5. Tassell MC et al. (2010). Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease. Pharmacogn Rev 4(7):32-41. — PubMed PMID: 22228939
  6. Garjani A, Nazemiyeh H, Maleki N, Valizadeh H (2000). Effects of extracts from flowering tops of Crataegus meyeri A. Pojark. on ischaemic arrhythmias in anaesthetized rats. Phytother Res 14(6):428-431. — PubMed PMID: 10960896
  7. Schwinger RH et al. (2000). Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 35(5):700-707. — PubMed PMID: 10813370
  8. Joseph G, Zhao Y, Klaus W (1995). [Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart] (in German). Arzneimittelforschung 45(12):1261-1265. — PubMed PMID: 8595081
  9. Holubarsch CJ, Colucci WS, Meinertz T, et al. (2008). The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 10(12):1255-1263. — PubMed PMID: 19019730
  10. Zick SM, Vautaw BM, Gillespie B, Aaronson KD (2009). Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. Eur J Heart Fail 11(10):990-999. — PubMed PMID: 19789403
  11. Iwamoto M, Sato T, Ishizaki T (1981). [The clinical effect of Crataegutt in heart disease of ischemic or hypertensive origin. A multicenter double-blind study] (in German). Planta Med 42(1):1-16. — PubMed PMID: 7019949
  12. Weng WL, Zhang WQ, Liu FZ, et al. (1984). Therapeutic effect of Crataegus pinnatifida on 46 cases of angina pectoris — a double blind study. J Tradit Chin Med 4(4):293-294. — PubMed PMID: 6397664
  13. Jalaly L, Sharifi G, Faramarzi M, et al. (2015). Comparison of the effects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-1 and E-Selectin in patients with stable angina pectoris. Daru 23:54. — PubMed PMID: 26687477
  14. Hopper I, Connell C, Briffa T, et al. (2020). Nutraceuticals in patients with heart failure: a systematic review. J Card Fail 26(2):166-179. — PubMed PMID: 31704198

PubMed Topic Searches

  1. PubMed: Crataegus ischemia/reperfusion
  2. PubMed: Hawthorn antioxidant cardioprotection
  3. PubMed: Crataegus angina
  4. PubMed: Hawthorn arrhythmia refractory period
  5. PubMed: Crataegus coronary vasodilation

Back to Table of Contents

Connections

Back to Table of Contents